Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice: The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome Prospective Open Label Antiplatelet Therapy Study
暂无分享,去创建一个
K. Anstrom | T. Henry | E. Peterson | M. Effron | D. Cohen | B. Baker | Tracy Y. Wang | D. Angiolillo | P. Berger | E. Honeycutt | Connie N. Hess | M. Zettler | D. Cohen | D. Cohen
[1] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[2] K. Huber,et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention , 2013, European heart journal.
[3] Deepak L. Bhatt,et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.
[4] Laura Mauri,et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[5] Peter L Duffy,et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.
[6] R. Abbate,et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. , 2013, Journal of the American College of Cardiology.
[7] Seung‐Jung Park,et al. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. , 2013, American heart journal.
[8] E. Vicaut,et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.
[9] K. Anstrom,et al. Abstract 15573: In-Hospital Switching of ADP Receptor Inhibitors in Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the TRANSLATE-ACS Study , 2012 .
[10] G. Stone,et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.
[11] W. Kim,et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. , 2012, JACC. Cardiovascular interventions.
[12] Jeroen J. Bax,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .
[13] Hani Jneid,et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.
[14] K. Anstrom,et al. Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. , 2011, American heart journal.
[15] M. Price,et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. , 2011, Journal of the American College of Cardiology.
[16] D. Angiolillo. Applying platelet function testing in clinical practice: what are the unmet needs? , 2011, JAMA.
[17] Betti Giusti,et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. , 2011, JAMA.
[18] P. Teirstein,et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial , 2011, Circulation.
[19] T. Lauer,et al. Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .
[20] M. Pansieri,et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. , 2011, Journal of the American College of Cardiology.
[21] J. Marchesini,et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. , 2011, Journal of the American College of Cardiology.
[22] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[23] N. Schork,et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.
[24] V. Deneer,et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. , 2010, JAMA.
[25] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[26] Françoise Dignat-George,et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. , 2009, The American journal of cardiology.
[27] P. Barragan,et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. , 2008, Journal of the American College of Cardiology.
[28] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[29] C. Macaya,et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.
[30] M. Furman,et al. Evidence that pre‐existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’ , 2007, Journal of thrombosis and haemostasis : JTH.
[31] F. Neumann,et al. Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention , 2005, Circulation.
[32] Deepak L. Bhatt,et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.
[33] Carl J Pepine,et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.
[34] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.